Top Ten most popular articles on Pharmafile.com this week!
pharmafile | January 25, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AbbVie, Celgene, NHS, health, pharma, venlytxo
While American firm AbbVie gained approval for leukaemia drug Venlytxo, the NHS defeated the US multinational thus week in court, after the firm challenged NHS England’s hep C drug procurement process, calling it ‘unfair’.
Meanwhile Sir Philip Hampton stepped down from his position as chairman of GSK while Vertex were prompted to oust current COO Ian Smith citing ‘personal behaviour’.
Meanwhile GSK bought Tesaro for $5.1 billion as Celgene signed deals with two east coast biotechs Kyn and Obsidian.
Check out this week’s top ten most popular stories!
10. Celgene signs deals with two Massachusetts-based biotechs
New Jersey-based biotechnology firm Celgene has signed deals with two Massachusetts-based biotechs: immuno-oncology specialist Kyn therapeutics and cell therapy firm Obsidian.
9. Pharmacists warn of shortages in England
Pharmacists have warned that they are struggling to obtain many common generic medicines, as the number of medicines on the ‘shortage of supply’ list has almost doubled since October 2018. Pharmacists are paying higher prices as a result.
8. Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s Venclyxto (venetoclax) in combination with Genentech’s Rituxan (rituximab) on the NHS as a treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) following one prior therapy.
7. Philip Hampton to step down from chairman role at GSK
Sir Philip Hampton is stepping down from his role as non-executive chairman of British multinational GlaxoSmithKline. The resignation comes just weeks after the firm announced it would split its business in two.
6. Sun Pharma’s shares hit six-year low after further whistleblower allegations emerge
Sun Pharma has seen its shares fall by 12% to an almost six-year low after it was rocked by allegations raised by a whistleblower at the company – the second such incident in little over a month.
5. NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma
Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by UK drug watchdog NICE for the treatment of unresectable or metastatic melanoma in adult patients with a BRAF V600 mutation, it has emerged.
4. AbbVie’s case against the NHS thrown out of court
A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court.
3. Canada Health approves Novartis’ CAR-T therapy Kymriah
Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and twenty-five years old with B-cell acute lymphoblastic leukaemia (ALL) and for adults with relapsed or refractory (r/r) large B-cell lymphoma.
2. GSK acquires oncology firm Tesaro for $5.1 billion
British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion).
1. Vertex ousts COO Ian Smith over ‘personal behaviour’
Boston-based firm Vertex Pharmaceuticals has fired Chief Operating Officer (COO) and interim Chief Financial Officer (CFO) Ian Smith. Smith’s termination, which is said to be unrelated to the company’s financial and business performance is effective immediately.
Related Content
AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
FDA approves AbbVie’s Skyrizi for UC treatment
AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) …
AbbVie initiates phase 3 multiple myeloma trial
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO …
